Capricor TherapeuticsCAPR
Recorded

Capricor Therapeutics Study result

Review the key takeaways and the transcript of this earnings call.

Period 0Duration1 hr 3 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Linda MarbánCEO and Director

Good morning or good afternoon, depending upon where you are. I want to thank you for joining today's call. I also want to thank PPMD for making this presentation possible and look forward to your questions at the end. Today, we will present an update on Deramiocel for the treatment of Duchenne muscular dystrophy, including our updates on our most recent data presented at the World Muscle Society in Hiroshima, Japan last week. Next slide, please. Next slide, please. This is Capricor's standard forward-looking statement that we present as a publicly traded company. To remind you, our filings are up to date and available on the SEC website. Next slide. As you just heard from Eric, joining me on today's call is Dr. Nathaniel Hogan and Dr. Adam Sullivan, two of Capricor's lead biostatisticians, as well as Dr. Craig McDonald, our national PI, who hails from the University of California, Davis, as well as Dr. Chet Villa, a pediatric cardiologist from Cincinnati Children's Hospital Medical Center, obviously in Cincinnati, Ohio.

Linda MarbánCEO and Director

We are looking forward to updating the DMD community on the recent developments around Deramiocel, including what has been submitted to the FDA. We will not take questions today regarding our interactions with FDA, as they are sensitive, and it is important to maintain that confidentiality. Thank you for respecting that guidance, and we look forward to providing updates as they become available on our BLA application. Now, let's talk about Deramiocel and Duchenne muscular dystrophy, the important topics of today. Next slide, please. While we were disappointed in the vote by the advisory committee, we were pleased that the FDA recognized and heard the voices of the patients, primarily in the open public hearing, and decided to extend the PDUFA date to November 22nd in order to review the additional data from the open-label extension and the supportive evidence that HOPE-3 did in fact demonstrate a clinical as well as statistically significant effect on treating both upper limb dysfunction in a primarily non-ambulant DMD population, and also in treating the cardiomyopathy associated with DMD.

Linda MarbánCEO and Director

We believe exciting OLE data presented today will be important in moving that program forward.

Linda MarbánCEO and Director

To remind you, the HOPE-3 data showed a 4.55% improvement in Performance of the Upper Limb 2.0 in those treated with Deramiocel at 12 months compared to a placebo group based on the statistical analysis plan we submitted, which was statistically significant, showing the trial met its primary efficacy endpoint of Performance of the Upper Limb 2.0. We use percent change from baseline as the primary efficacy endpoint because as data continues to emerge, it appeared that the best way to assess the Performance of the Upper Limb and also the clinical meaningfulness to a person with DMD, primarily based on the work of Aviva Gilman and Anna Mayhew, published in 2025. However, we saw statistically significant and clinically meaningful improvement in absolute change from baseline in PUL 2.0.

Linda MarbánCEO and Director

No matter how you look at it, the data shows a benefit in sustaining upper limb function in those with advanced DMD. I do not have to reiterate this to you, but HOPE 3 represents one of the largest DMD datasets ever collected, and therefore, there is true strength in the data, as you will see in the presentation from Dr. Nathan Hogan in a few minutes. FDA granted us a refinement of the indication from cardiomyopathy to one more focused on what HOPE 3 was powered to detect, which was a change in upper limb function. The new indication, therefore, is for treating those with upper limb impairment at ages greater than 9, which encompasses a large proportion of those with DMD. Next slide, please. As I just mentioned, the new refined indication is treatment of upper limb impairment in those older than age 9.

Linda MarbánCEO and Director

How did we get there? Let me provide some context, please. Most of you know we filed a BLA based on the HOPE 2 and the HOPE 2 OLE results based on recommendation from FDA that we do so. Upon their review, they decided the dataset was too small and issued a CRL in July of 2025 asking for a new trial with DMD cardiomyopathy as the primary efficacy endpoint. However, since we had a complete dataset in HOPE 3 and 106 of you had enrolled in that study, we offered them HOPE 3 as a way to cure the CRL. They agreed and requested we leave the indication as DMD cardiomyopathy and maintain the primary efficacy endpoint as PUL 2.0. They stated in writing regulatory flexibility when they reviewed the data.

Linda MarbánCEO and Director

As you know, based on their briefing book for the advisory committee meeting, their interpretation of the HOPE 3 data was very different from ours, primarily based on the fact that they used a statistical analysis plan, version 1.1, that was never meant to be applied to the full dataset. In addition, the key secondary endpoint of HOPE 3 was the left ventricular ejection fraction in the ITT population. ITT is intent to treat, and that means everybody that enters into the trial has to be analyzed. One-third of those in the intent to treat population had healthy hearts. While the data was strongly suggestive of clinical benefit, the strictest interpretation of that data did not show left ventricular ejection fraction as statistically significant.

Linda MarbánCEO and Director

However, and I want to reiterate, that is essentially a numeric interpretation because you cannot make a healthy heart healthier. This made interpretation of the voting question by the advisory committee regarding cardiomyopathy as an approvable endpoint more challenging. Today, Dr. McDonald will show data that those with DMD cardiomyopathy had sustained and statistically significant improvements in heart function as measured by left ventricular ejection fraction, which is the most important group to assess the benefits of Deramiocel in treating the cardiac dysfunction associated with DMD. You will also see that the upper limb data continues to be strong and that there is the durability of effect.

Linda MarbánCEO and Director

We are delighted that based on the strong support from the DMD community and the major unmet medical need, the FDA allowed us to submit a major amendment. The data submitted to the FDA and those data from the open-label extension recently presented at the World Muscle Society will be shown here today for you. Next slide, please. To remind you and for your review, the results from HOPE-3 were recently published in The Lancet, one of the top medical journals in the field. We will not focus on that data today except to provide the context I mentioned earlier. We are proud of the results from HOPE-3 and believe that The Lancet reviewers carefully assessed the data prior to accepting the manuscript.

Linda MarbánCEO and Director

Please feel free to reach out to us at Capricor or any of the authors of the paper for further context around the HOPE-3 data should you have any questions after today's presentation. Next slide, please. To remind you, we have been looking at treating DMD for a long time now. What we take great comfort in is the consistency of the data across multiple clinical trials, as well as over 1,000 infusions over 8 years. Each clinical trial from HOPE-2 onwards showed clinical relevance with at least a 1-point change in the Performance of the Upper Limb 2.0 in those treated with Deramiocel compared to the placebo group or the natural history cohort. In a few minutes, Dr. McDonald will show you what a 1-point change looks like, and many of you on this call can tell us what a 1-point change feels like.

Linda MarbánCEO and Director

Importantly, one key element of alignment with the FDA has been that a 1-point change in the PUL 2.0 is clinically relevant. I would like to thank you for taking time out of your day to join us and hear about the new data from the open-label extension and also why we believe in the strength and the lack of fragility of the HOPE-3 data. Now, I will ask Dr. McDonald to present the new 2-year open-label extension data from the HOPE-3 clinical trial.

Craig McDonaldNational PI

Thank you. Craig? Great. Thank you, Linda.

Craig McDonaldNational PI

I am really pleased to be able to present these updated data that really focus on longer-term treatment effects in the HOPE-3 trial participants. I will be discussing today an overview of the HOPE-3 open-label extension study, where patients were followed out for an additional year after the original randomized placebo-controlled clinical trial. We will discuss some HOPE-3 open-label extension skeletal muscle upper limb functional results, as well as some cardiac MRI results. We will also provide some update with regard to the open-label extension safety data as well. Next slide. Before I get into the data, what I would really like to emphasize is that a 1-point change in the PUL 2.0, there is no question, has been determined to be clinically meaningful.

Craig McDonaldNational PI

The FDA has actually provided feedback to Capricor on a number of occasions, written feedback that they believed a 1-point change in the PUL 2.0 was clinically meaningful and clinically relevant. In addition, I was actually quite pleased to see that the FDA actually, in their slide presentation, actually stated in their slides that they believe that a 1-point change in the PUL 2.0 was clinically meaningful and clinically relevant. Just to illustrate this actually demonstrates on one of the functions of the PUL, the bringing hand to mouth function, which has been deemed by the DMD community to be one of the most important of functional issues related to quality of life in a non-ambulatory population, the ability to bring the hand to the mouth and feed oneself independently. On the left, if we could click this first image here.

Craig McDonaldNational PI

This patient actually is bringing the cup fully to the mouth without compensation. They actually have a 200 gram weight in that cup. They are easily able to bring that cup to the mouth without any compensation. This would be scored as a score of 2 on the bringing hand to mouth function. If we go to the next slide, this is a patient with more advanced DMD. This patient actually is still able to bring the hand to the mouth, the cup to the mouth, but they do so with compensation. As you can see it here in this image, they have to lean forward quite a bit. They use their other extremity to help bring the arm up to the mouth. They would actually be scored as a 1-point score on the bring hand to mouth function.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day